semaglutide prediabetes progression to type 2 diabetes trial Effect of 2.4 mg once weekly on 10‐year risk in adults with overweight or obesity - Wilkinson - 2023 - Obesity Efficacy and safety of once-weekly

Semaglutide GLP-1 injections contain a peptide very similar to glucagon, a hormone that we naturally produce to help lower our blood sugar after eating by stimulating insulin release and blocking the production of sugar

What we'd expect long-term based on available data: Weight loss continues through at least 104 weeks in most patients Estimated peak loss: 3032% in patients reaching maximum dose and maintaining treatment Maintenance phase: stable weight if treatment continues without dose reduction Weight regain after stopping is near-universal with all GLP-1 medications

The synergy is mechanistic, not anecdotal

Through modification, its molecular size is reduced so it dissolves more easily and interacts differently in the body than standard dietary pectin

Its imperative to be aware of the legal implications, especially in sports and competitive arenas where restrictions on certain peptides may be in place